Additionally, TACSTD2 serves as a marker of poor prognosis in various solid tumours, such as breast, ovarian, prostate, hepatocellular, and oral squamous cell carcinomas [39–41]. The gene discussed is TACSTD2; the disease is oral cavity squamous cell carcinoma.